Drug-induced Liver Injury (DILI)
Current status and future directions for drug development and the post-market setting.
This consensus report of the CIOMS DILI Working Group aims to provide a critical framework and essential set of tools to detect, diagnose, and manage DILI during drug development and in the post-marketing setting. The report is intended for clinical and basic pharmaceutical industry investigators who capture, analyze, and communicate liver safety data in drug development. It is also intended for regulatory scientists and expert consultants who comprehensively evaluate new products and emerging biomarkers for their association with DILI risk and for health care professionals who monitor and manage patients treated with potentially hepatotoxic drugs in clinical practice.